Background. Studies suggest that the 7-valent pneumococcal conjugate vaccine (PCV7) reduces carriage of vaccine-type (VT) Streptococcus pneumoniae (SP). We studied the effect of PCV7 on carriage of VT-and non-VT (NVT) SP, by studying the effect of PCV7 on nasopharyngeal (NP) colonization by VT and NVT SP during early childhood.
carriage rates peak among children of preschool age [1, 2] . Carriers usually remain asymptomatic but can transmit the organism to others.
Haemophilus influenzae conjugate vaccines have been successful in reducing NP carriage of this organism in infants and children, which has contributed greatly to the success of immunization programs, by providing a substantial herd effect [3, 4] . We, as well as other researchers [5] [6] [7] , have postulated that vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7) would have an effect on pneumococcal carriage similar to that seen with the H. influenzae conjugate vaccine. However, factors affecting carriage and serotype replacement are complex, and the effect of vaccination on the carriage of different organisms will vary. The pneumococcal polysaccharide-protein conjugate vaccines have been shown to be highly immunogenic for infants [8, 9] , and studies have suggested that these vaccines reduce NP carriage of vaccine-type (VT) pneumococci in toddlers, possibly by preventing acquisition rather than by eradicating established SP colonization Downloaded from https://academic.oup.com/cid/article-abstract/39/7/930/494654 by guest on 21 March 2019 [3, 10] , but that they increase carriage of non-VT (NVT) pneumococci [11] [12] [13] [14] . These studies, however, were performed in areas of the world that possibly have a different pneumococcal epidemiology than that seen in the United States.
Results of studies of the effect of PCV7 on NP colonization among US infants receiving the primary vaccine series during infancy and the booster dose at 12-15 months of age have not been published. Thus, the primary objective of this study was to determine the effect of vaccination with primary and booster doses of PCV7 on NP colonization by VT strains of SP. Additional objectives were to investigate whether a reduction in the rate of carriage of VT pneumococci is associated with a parallel increase in the rate of carriage of NVT pneumococci and to assess whether the administration of this vaccine results in reduction of carriage of antimicrobial-resistant SP.
METHODS
Study population. At 2 months of age, 150 infants who were to receive primary immunizations were enrolled from a private practice in Plano, TX. Similarly, at 2 months of age, a second group of 128 infants were enrolled from the Continuity Care Clinics of Children's Medical Center in Dallas. The enrollment period was September 2000 through August 2001.
Inclusion criteria were male or female children of any race or ethnicity who were 2 months of age, were candidates to receive primary immunizations, and were available for followup visits. Exclusion criteria were hypersensitivity to any component of the vaccine, including diphtheria toxoid. Swabs (calcium alginate, cotton tipped [Fisher]) were used to obtain NP samples at 2, 4, 6, and 12-15 months of age, before each dose of PCV7; at 9 months of age; and at 15-18 months of age, 2-3 months after the booster dose of vaccine. These subjects were followed up until 15-18 months of age for collection of data regarding acquisition, persistence, and clearance of NP colonization by SP.
NP samples from all subjects were obtained by introducing the swab into the nostril and advancing until resistance was found. At the time of enrollment, the following information was recorded from office chart records for each child: age, sex, number of siblings, age of siblings, hours of day care attendance, type of day care attendance, presence of any underlying illness, and history of acute otitis media and of antibiotic therapy within 1 month prior to enrollment. Information regarding day care attendance, history of acute otitis media, prior use of antibiotic therapy, and presence of siblings in the household was also obtained at the 12-15-month and 15-18-month visits.
Parents gave informed, written permission for enrollment of their child. The study protocol was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center at Dallas, and clinical research was conducted in accordance with the guidelines for human experimentation of the US Department of Health and Human Services.
Microbiological analysis. Swabs used to collect NP samples were kept moist in nutrient broth and were stored at 4ЊC for a maximum of 12 h before samples were plated. NP samples were plated onto trypticase soy agar with 5% sheep blood. In an effort to distinguish between coresiding penicillin-susceptible and penicillin-nonsusceptible (PNS) strains, 2 sets of blood-agar plates-one with 0.1 mg/mL penicillin and one without penicillin-were used. All blood-agar plates contained 1 mg/mL gentamicin. a-hemolytic colonies growing on bloodagar plates containing 0.1 mg/mL penicillin were inoculated onto plates containing 1 and 2 mg/mL penicillin, to separate pneumococcal strains with different penicillin susceptibilities. Two a-hemolytic colonies from each type of blood-agar plate (with and without penicillin) were tested for each patient (the colonies were selected randomly, except when morphologically distinct colonies were present). Pneumococci were distinguished from other a-hemolytic streptococci on the basis of colony morphology, optochin inhibition (ethylhydrocupreine; Difco) [15] , and bile solubility (10% sodium desoxycholate [Bactidrop; Difco]).
Susceptibility of SP to penicillin, cefotaxime, and azithromycin was determined by use of the epsilometric test (Etest; AB Biodisk) [16] . SP isolates were classified as penicillin susceptible (MIC, р0.06 mg/mL), intermediate penicillin resistant (MIC, 10.06-1.0 mg/mL), or penicillin resistant (MIC, 11.0 mg/ mL) and as cefotaxime or azithromycin susceptible (MIC, р0.5 mg/mL) or resistant (MIC, 10.5 mg/mL). These definitions have been modified from NCCLS guidelines [17] to include results from Etest strips that fall between those defined for microdilution methods. The category PNS includes both intermediate penicillin-resistant and penicillin-resistant strains.
Serogroups and serotypes of SP isolates were determined by the Neufeld-Quellung reaction, using pooled Danish (80 serotypes) and individual (serotypes 6A, 6B, 9A, 9L, 9N, 9V, 19F, 19A, 19B, 19C, 23F, 23A, and 23B) pneumococcal serotypespecific antiserum samples [18] . Isolates that tested negative by all pooled and individual pneumococcal serotype-specific antiserum samples were classified as nontypeable. Isolates that tested positive for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F were classified as VT pneumococci. Serotypes in the same serogroup as the VT serotypes were classified as vaccine-related serotypes (6A, 19 non-F, 23 non-F, and 9 non-V). Serotypes other than VT were classified as NVT.
DNA analysis. DNA-fingerprint patterns were determined for pneumococcal isolates with similar MICs for penicillin, cefotaxime, and azithromycin, to determine their genetic relatedness and the possibility of serotype switching. Strain-specific genomic DNA-fingerprint patterns for SP were determined by using the enterobacterial repetitive intergenic consensus (ERIC) 
Age, years (range) р5 1R/ERIC 2 PCR primer sets [19] . In addition, the genotypic profile of penicillin-binding protein (PBP) in pneumococcal NP isolates was determined by using PCR and restriction fragment-length polymorphism analyses for the 1a, 2b, and 2x binding sites [20, 21] . Strains of SP were considered to be identical if no change was found in the repetitive-PCR fingerprint pattern or the PBP fingerprint pattern, other than a 1-band difference at the 1a gene. Patterns of pneumococcal colonization also were determined on the basis of susceptibility testing, serotyping, and, in selected cases, by analysis of repetitive-PCR fingerprint patterns. New acquisition of SP by a subject was defined as colonization with a strain not isolated at a previous visit, persistent colonization was determined when the same isolate was present at a subsequent visit, and clearance was determined when the pneumococcal strain was not isolated at a subsequent visit.
Statistical analysis. Statistical analyses were performed by use of SPSS software, version 11.0 (SPSS). Group comparisons were made between subjects recruited from the private practice and those from Continuity Care Clinics, between subjects with and those without SP colonization, and between subjects with and those without penicillin resistance. Sex, ethnicity, number of siblings, day care attendance, history of acute otitis media, antibiotic usage and resistance, and rate of SP colonization were compared by using x 2 analysis or Fisher's exact test. Proportions of children with colonization by SP, VT or NVT SP, and penicillin-susceptible or PNS pneumococci were calculated at 2, 4, 6, 9, 12-15, and 15-18 months of age. Overall, the trend of pneumococcal carriage across the 6 data points was analyzed by using Cochran's Q test for related proportions. This analysis only included those subjects who were present at all datacollection time points, and no imputation of missing values was performed. The McNemar test was performed to determine the significance at each consecutive time point (e.g., 2 vs. 4 months of age). Similar analyses were performed to analyze the patterns of pneumococcal colonization (new acquisition, persistent colonization, or clearance) for each relevant time point and for changes during the study period. All data are reported as median values (ranges) or as percentages (95% CIs). Post hoc comparisons were corrected by means of the Bonferroni method for multiple comparisons.
RESULTS
The study cohort consisted of a total of 278 subjects (150 from private practice and 128 from Continuity Care Clinics). The baseline characteristics of the group of children enrolled from both sites are given in table 1. Approximately one-half (53% [95% CI, 44%-62%]) of the subjects recruited from Continuity Care Clinics were of a minority ethnicity, compared with only 11% (95% CI, 6%-16%) from the private practice. Forty-three percent (95% CI, 37%-49%) of the study cohort was male; the median number of siblings was 0 (range, 0-7), and the median number of household members was 4 (range, 2-10), for the study population. Only 4% of subjects (95% CI, 2%-6%) were attending day care centers at 2 months of age, compared with 16% (95% CI, 11%-21%) and 16% (95% CI, 11%-21%) at 12-15 and 15-18 months of age, respectively. A history of acute otitis media was reported for 9% of subjects (95% CI, 6%-12%) at enrollment, for 21% (95% CI, 15%-27%) at the 12- 15-month visit, and for 13% (95% CI, 8%-18%) at the 15-18-month visit. The use of an antibiotic within 1 month prior to study enrollment was reported for 16% of subjects (95% CI, 12%-20%), compared with 41% (95% CI, 34%-48%) at the 12-15-month visit and 29% (95% CI, 22%-36%) at the 15-18-month visit. No significant difference was found between subjects from the private practice and those from Continuity Care Clinics for day care attendance, history of acute otitis media, antibiotic use within 1 month prior to a study visit, pneumococcal colonization, and colonization with PNS strains (table 1) . The association of variables of interest with pneumococcal colonization and colonization with PNS strains is given in table 2. Penicillin-resistant strains were found in 18% (95% CI, 5%-31%) of the subjects with pneumococcal colonization at enrollment; this proportion increased to 53% (95% CI, 40%-66%) at the 12-15-month visit and then dropped to 35% (95% CI, 22%-48%) at the 15-18-month visit. Day care attendance, (6) 27 (11) 32 (14) 27 (14) 35 (18) (6) 17 (7) 22 (10) 30 (16) 23 (12) 32 (18 (2) 23 (10) 27 (12) 30 (16) 31 (16) 17 (9) !.001 (10) 21 (9) 27 (12) 27 (14) 27 (14) 31 (17 (7) 20 (9) 16 (8) 25 (13) NT  3  2  1  3  0  3   UC  1  1  3  4  3  4  Total  15  8  9  17  12  22 NOTE. NT, nontypeable; UC, uncommon (any serotype other than the serotypes listed).
history of acute otitis media, antibiotic usage within 1 month prior to a study visit, and the presence of siblings were not found to be significantly associated with either pneumococcal colonization or carriage of PNS SP strains (table 2) .
NP carriage of SP was found in 12% of subjects (95% CI, 8%-16%) at 2 months of age and increased slightly to 18% (95% CI, 13%-23%) at 4 months of age. SP carriage remained in 24%-30% of subjects during the subsequent months. The ratio of the number of subjects with VT-SP colonization versus the number with NVT-SP colonization was ∼1.0 at 2 months of age, increased to 1.5 at 4-6 months of age, and decreased to 0.5 after the booster dose of vaccine (as determined at the 15-18-month visit). Significant trends were found for the carriage rates of VT SP and NVT SP over the course of the study ( ). Carriage of VT strains in-P p .001 creased steadily, from 6% of subjects (95% CI, 3%-9%) at enrollment to 18% (95% CI, 13%-23%) at the 12-15-month visit, and then dropped significantly to ∼9% of subjects (95% CI, 5%-13%) at the 15-18-month visit. Carriage of NVT strains showed a similar trend for the first 5 study visits (until the 12-15-month visit) but, unlike the carriage of VT strains, remained high after the booster dose of vaccine (as determined at the 15-18-month visit). Significant trends also were seen for the carriage rate of PNS SP ( ), which showed P ! .001 a sharp increase from 2% of subjects (95% CI, 0%-2%) at 2 months of age to 10% (95% CI, 6%-14%) at 4 months of age and then a gradual increase to 16% (95% CI, 11%-21%) by 12-15 months of age. The carriage rate of PNS SP strains showed a clear declining trend after the booster dose of vaccine (9% of subjects [95% CI, 5%-13%]), but this change was not statistically significant, probably because of a lack of power in the post hoc test. The carriage rate of penicillinsusceptible SP remained at 9%-17% of subjects, and no significant change was observed (table 3) .
Even though the overall rate of new acquisition of SP did not change significantly throughout the study period, significant trends were observed for the separate rates of acquisition of VT and NVT strains. The acquisition rate of VT SP dropped significantly, from 13% of subjects (95% CI, 8%-18%) at the 12-15-month visit to 4% (95% CI, 1%-7%) at the 15-18-month visit, and the acquisition rate of NVT SP increased, from 8% (95% CI, 4%-12%) to 15% (95% CI, 10%-15%), during the same time period (table 3) Serotype switching among pneumococcal isolates could not be documented. Of the isolates with VT serotypes, 78% (120 of 153) were PNS, versus 13% (8 of 58) of isolates with vaccinerelated serotypes and 7% (6 of 83) with NVT serotypes.
DISCUSSION
In this study, we demonstrated that the carriage of VT SP decreased significantly after the booster dose of PCV7 was given in the second year of life. Dagan et al. [3, 10] also showed a reduction in NP carriage of VT SP when heptavalent and nonavalent pneumococcal conjugate vaccines were given during the second year of life. The reduction in carriage and spread of the VT serotypes will be instrumental in creating a herd effect for a reduction in the carriage of VT SP and the incidence of disease caused by VT SP, among unimmunized individuals in contact with vaccine recipients [13, 22] . Furthermore, Dagan et al. [23] reported that vaccination of toddlers, aged 12-35 months, with a 9-valent pneumococcal conjugate vaccine resulted in a reduction in carriage of VT and antibiotic-resistant SP among their younger siblings.
Pneumococcal conjugate vaccine induces mucosal antibodies. Anti-polysaccharide antibodies-namely, either IgA or IgG-are rarely detected in the saliva of 7-month-old infants after vaccination with the primary series of PCV7. However, after vaccination with the booster dose of PCV7, IgA and IgG are detected in saliva in 12%-81% of 16-month-old children, depending on the serotypes included in the vaccine [12, 24] . In these and other studies, a positive correlation between serum and salivary IgG levels has been found, which supports the idea that salivary IgG is diffused from serum [25, 26] .
The timing of the appearance of mucosal IgA and IgG may explain the significant reduction in carriage of VT SP that was seen in our study, after the booster dose was given, and the replacement with NVT pneumococci. As a result, the overall prevalence of pneumococcal carriage among vaccinated children did not change significantly. This finding also has been reported elsewhere [13, 14, 22, 23, [27] [28] [29] . In Gambia, carriage of nonvaccine serotypes was found in 79% of children receiving 3 doses of a pneumococcal conjugate vaccine, compared with 42.5% of control subjects [13] . In trials of a 9-valent pneumococcal conjugate vaccine in southern Israel, NP carriage of vaccine serotypes was found in 17% of vaccine recipients, compared with 51% of control subjects. In contrast, carriage of nonvaccine serotypes was found in 68% of vaccine recipients and in 28% of control subjects [23] . The results of these studies indicate that replacement of vaccine serotypes by nonvaccine serotypes in the nasopharynx is likely after universal implementation of vaccination with pneumococcal conjugate vaccine. Serotype replacement has been suggested to occur when extensive contact with children carrying NVT pneumococci occurs or, alternatively, when multiple serotypes are carried and an unmasking phenomenon occurs after reduction of carriage of VT pneumococci in response to vaccination [11] .
The decrease in carriage of and disease caused by vaccine serotypes should reduce the incidence of disease caused by antibiotic-resistant pneumococci. This reduction is likely to have its greatest impact on cases of upper-respiratory illness, of which an increasing proportion is attributed to nonvaccine serotypes that are currently susceptible to penicillin and other antibiotics [29] . The pneumococcal conjugate vaccines are unlikely to have a sustained effect on the prevalence of acute otitis media, because serotype replacement following vaccination results in middle-ear disease caused by pneumococci of nonvaccine serotypes, as shown by the results of 2 trials of conjugate vaccines in Finland [29, 30] .
In the present study, we demonstrated that, after the booster dose of vaccine, the decrease in colonization with vaccine serotypes was secondary to decreased acquisition of these serotypes. This observation is similar to those made following vaccination with H. influenzae type b and nonavalent pneumococcal conjugate vaccines [10, 31] . The decrease in carriage of vaccine serotypes that is concomitant with replacement by nonvaccine serotypes, after the booster dose of vaccine, provides an understanding of the increase in episodes of acute otitis media caused by nonvaccine serotypes that was observed in the Finnish study [30] and of the maximum effectiveness of PCV7 in the prevention of otitis media at 15-17 months of age that was reported by the Northern California Kaiser Permanente Vaccine Study Group [32] .
As suggested by the reduction of colonization by VT pneumococci after vaccination and the replacement by NVT pneumococci that was observed in this study, universal immunization of a dense population with a high rate of pneumococcal colonization and spread, such as that in a day care center, will result in replacement of pneumococci by new serotypes not included in the vaccine. Ongoing surveillance of isolates from the nasopharynx and sterile body sites is critical, because changes in the susceptibility patterns among nonvaccine serotypes can occur with time; thus, reconsideration of recommendations for treatment of pneumococcal disease will be important.
